Although most guidelines continue to recommend metformin as first-line anti-hyperglycemic therapy, the European Society of Cardiology [52] recommends that GLP-1RA or SGLT2i should be first-line therapy in individuals with ASCVD or at high or very high CV risk
The number grows every month
The ability of oral semaglutide to improve glycaemic control and reduce body weight, as well as its effect on other clinical outcomes, are currently being investigated in phase III clinical trials
El orlistat acta inhibiendo la absorcin intestinal de las grasas alimenticias, lo que puede reducir la ingesta calrica y, en consecuencia, la prdida de peso
These medications can be expensive, and not all insurance plans cover them, which may limit your access
Sleep got worse: Poor sleep wrecks hunger hormones and recovery